Servier's TIBSOVO® (Ivosidenib Tablets) Granted FDA Acceptance and Priority Review for Treating IDH1-Mutated Relapsed or Refractory Myelodysplastic Syndrome
Servier, a renowned player in the field of oncology dedicated to advancing patient care, has made a significant announcement. The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for TIBSOVO® (ivosidenib tablets) and has granted it Priority Review. This comes as a milestone for TIBSOVO's potential use in treating patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS). If approved, TIBSOVO would represent a groundbreaking targeted therapy option for MDS patients within this specific molecular subgroup.
While targeted IDH inhibition has shown promise in various challenging-to-treat cancers, there remains a significant unmet medical need for patients with MDS, especially those facing disease progression. The acceptance of this application underscores the potential efficacy and safety profile of TIBSOVO in the treatment of relapsed or refractory MDS. It also emphasizes the critical role of mutational testing in identifying suitable candidates within this patient population.
Priority Review designation is reserved for medications with the potential to provide substantial improvements in treatment effectiveness or safety for serious medical conditions. TIBSOVO had previously received FDA Breakthrough Therapy designation for its use in adult patients with R/R MDS harboring a specific IDH1 mutation, as confirmed by an FDA-approved test.
Currently, TIBSOVO is approved in the U.S. for various indications, including monotherapy for adults with IDH1-mutant R/R acute myeloid leukemia (AML) and in combination with azacitidine for newly diagnosed IDH1-mutant AML patients who are ≥75 years old or have comorbidities that preclude intensive induction chemotherapy.
The European Commission has also recently granted approval for TIBSOVO for two distinct indications: in combination with azacitidine for newly diagnosed AML patients with an IDH1 R132 mutation who are not eligible for standard induction chemotherapy, and as a monotherapy for patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who have received at least one prior line of systemic therapy.
Myelodysplastic Syndromes (MDS) represent a group of disorders characterized by immature blood cell development. In the United States, approximately 16,000 new cases of MDS are reported each year, with about a third of these patients eventually progressing to acute myeloid leukemia (AML). Approximately 3.6% of MDS patients carry an IDH1 mutation, which is associated with poorer overall outcomes and is considered an early "driver" mutation in the transition from MDS to AML. Treatment options for MDS include chemotherapy, supportive therapy, stem cell transplantation, growth factors, and related therapies.
